To re-censor, or not to re-censor, that is the question: Critical considerations when applying statistical methods to adjust for treatment switching in clinical trials
Nicholas Latimer
K.R. Abrams
10.15131/shef.data.11897421.v1
https://figshare.shef.ac.uk/articles/poster/To_re-censor_or_not_to_re-censor_that_is_the_question_Critical_considerations_when_applying_statistical_methods_to_adjust_for_treatment_switching_in_clinical_trials/11897421
To determine when re-censoring should be incorporated in
statistical analyses undertaken to adjust for treatment
switching in randomised controlled trials, and to
demonstrate the utility of inverse probability weighting
(IPW) as an alternative to re-censoring. Treatment
switching often has a crucial impact on estimates of the
effectiveness and cost-effectiveness of new oncology
treatments (Figure 1). Switching adjustment methods such
as rank preserving structural failure time models (RPSFTM)
and two-stage estimation (TSE) estimate â€˜counterfactualâ€™
(i.e. in the absence of switching) survival times and
incorporate re-censoring to guard against informative
censoring in the counterfactual dataset. However, recensoring often involves a loss of longer term survival
information which is problematic when estimates of longterm survival effects are required
2020-02-25 12:22:42
Statistical Methods
treatment switching
clinical trials